NIBEC

[Not Yet Scheduled]
NIBEC is established as a spin-off venture from Seoul National University, South Korea at 2004 and listed in Korean Stock Market (KOSDAQ) at 2011. The company's main technology is based on target oriented peptide therapeutic discovery (TOPscovery) platform for drug discovery and development. The company’s focus of therapeutic area are inflammatory diseases (NASH, IBD) and cancer with new mode of action. NIBEC has target tissue/cell penetrating peptide delivery platform to deliver protein/antibody into the target tissue such as cancer. The other advanced therapeutic program is for the treatment of osteoporosis facing phase I. In addition to the drug development, the company holds medical device manufacturer license for tissue engineering biomaterials, tissue regenerative therapy dedicated to bone healing. The company has two research institutes and one manufacturing facility with fully granted GMP.
Ticker:
138610
Exchange:
KOSDAQ (Korean Stock Market)
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2004
Main Therapeutic Focus:
Lead Product in Development:
Therapeutic peptide (preclinical and Phase I entering)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
8
Speaker